IL1B and type 2 diabetes mellitus: One patient with virus-negative inflammatory cardiomyopathy and decompensated type 2 diabetes mellitus was treated with high-dose immunoglobulin and then with IL-1β inhibitor (anakinra) with improvement of ventricular function.